Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Bioven Ltd.
DescriptionPeptide vaccine comprising recombinant humanized epidermal growth factor (EGF) linked to a Neisseria meningitidis-derived recombinant immunogenic carrier protein P64k (rP64k), plus a montanide adjuvant
Molecular Target Epidermal growth factor receptor (EGFR)
Mechanism of ActionVaccine
Therapeutic ModalityActive immunotherapy
Latest Stage of DevelopmentPhase III
Standard IndicationNon-small cell lung cancer (NSCLC)
Indication DetailsTreat non-small cell lung cancer (NSCLC)
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today